Clinical prognostic factors in adults with astrocytoma: Historic cohort

被引:18
作者
Wegman-Ostrosky, Talia [1 ]
Reynoso-Noveron, Nancy [1 ]
Mejia-Perez, Sonia I. [2 ]
Sanchez-Correa, Thalia E. [2 ]
Alvarez-Gomez, Rosa Maria [1 ]
Vidal-Millan, Silvia [1 ]
Cacho-Díaz, Bernardo [3 ]
Sanchez-Corona, Jose [4 ]
Herrera-Montalvo, Luis A. [1 ]
Corona-Vazquez, Teresa [5 ]
机构
[1] Inst Nacl Cancerol, Direcc Invest, San Fernando 22,Secc 16, Tlalpan 14080, Cdmx, Mexico
[2] Inst Nacl Neurol & Neurocirug, Subdirecc Neurocirugia, Insurgentes Sur 3877, Tlalpan 14269, Cdmx, Mexico
[3] Inst Nacl Cancerol, Dept Neurooncol, San Fernando 22,Secc 16, Tlalpan 14080, Cdmx, Mexico
[4] IMSS, Cetro Med Occidente, Direcc Ctr Invest Biomed, Sierra Mojada 800, Guadalajara 44340, Jalisco, Mexico
[5] Inst Nacl Neurol & Neurocirug, Lab Clin Enfermedades Neurodegenerativas, Insurgentes Sur 3877, Tlalpan 14269, Cdmx, Mexico
关键词
Prognosis; Primary brain tumour; Cohort study; Astrocytoma; Life lost due to premature death; Glioblastoma; GRADE GLIOMAS; PHASE-III; GLIOBLASTOMA; SURVIVAL; MEXICO; EPIDEMIOLOGY; CHLOROQUINE; EXPERIENCE; ADJUVANT; ALCOHOL;
D O I
10.1016/j.clineuro.2016.05.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To explore the clinical prognostic factors for adults affected with astrocytoma. Patients and methods: Using a historic cohort, we selected 155 clinical files from patients with astrocytoma using simple randomization. The main outcome variable was overall survival time. To identify clinical prognostic factors, we used bivariate analysis, Kaplan Meier, the log rank test and the Cox regression models. The number of lost years lived with disability (DALY) based on prevalence, was calculated. Results: The mean age at diagnosis was 45.7 years. Analysis according to tumour stage, including grades II, III and IV, also showed a younger age of presentation. Kaplan-Meier survival estimates showed that tumour grade, Karnofsky status (KPS) >= 70, resection type, chemotherapy, radiotherapy, alcohol consumption, familial history of cancer and clinical presentation were significantly associated with survival time. Using a proportional hazard model, age, grade IV, resection, chemotherapy + radiotherapy and KPS were identified as prognostic factors.The amount of life lost due to premature death in this population was 28 years. Conclusion: In our study, astrocytoma was diagnosed in young adults. The overall survival was 15 months, 9% (n= 14) of patients presented a survival of 2 years, and 3% of patients survived 3 years. On average the number of years lost due to premature death and disability was 28.53 years. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:116 / 122
页数:7
相关论文
共 31 条
  • [1] Adeberg S., 2014, RAD ONCOL LONDON ENG, V23, P9
  • [2] American Cancer Society, 2013, CANC FACTS FIG 2015
  • [3] Treatment options and outcomes for glioblastoma in the elderly patient
    Arvold, Nils D.
    Reardon, David A.
    [J]. CLINICAL INTERVENTIONS IN AGING, 2014, 9 : 357 - 367
  • [4] Alcohol consumption and risk of glioblastoma; evidence from the Melbourne Collaborative Cohort Study
    Baglietto, Laura
    Giles, Graham G.
    English, Dallas R.
    Karahalios, Amalia
    Hopper, John L.
    Severi, Gianluca
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (08) : 1929 - 1934
  • [5] Elderly patients with glioblastoma: State of the art
    Biau, Julian
    Dalloz, Pierre
    Durando, Xavier
    Hager, Marie-Odile
    Ouedraogo, Zangbewende Guy
    Khalil, Toufic
    Lemaire, Jean-Jacques
    Chautard, Emmanuel
    Verrelle, Pierre
    [J]. BULLETIN DU CANCER, 2015, 102 (03) : 277 - 286
  • [6] Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium
    Bondy, Melissa L.
    Scheurer, Michael E.
    Malmer, Beatrice
    Barnholtz-Sloan, Jill S.
    Davis, Faith G.
    Il'Yasova, Dora
    Kruchko, Carol
    McCarthy, Bridget J.
    Rajaraman, Preetha
    Schwartzbaum, Judith A.
    Sadetzki, Siegal
    Schlehofer, Brigitte
    Tihan, Tarik
    Wiemels, Joseph L.
    Wrensch, Margaret
    Buffler, Patricia A.
    [J]. CANCER, 2008, 113 (07) : 1953 - 1968
  • [7] Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?
    Brandes, Alba A.
    Franceschi, Enrico
    Ermani, Mario
    Tosoni, Alicia
    Albani, Fiorenzo
    Depenni, Roberta
    Faedi, Marina
    Pisanello, Anna
    Crisi, Girolamo
    Urbini, Benedetto
    Dazzi, Claudio
    Cayenne, Luigi
    Mucciarini, Claudia
    Pasini, Giuseppe
    Bartolini, Stefanie
    Marucci, Gianluca
    Morandi, Luca
    Zunarelli, Elena
    Cerasoli, Serenella
    Gardini, Giorgio
    Lanza, Giovanni
    Silini, Enrico Maria
    Cavuto, Silvio
    Baruzzi, Agostino
    [J]. NEURO-ONCOLOGY PRACTICE, 2014, 1 (04) : 166 - 171
  • [8] Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme
    Briceno, Eduardo
    Calderon, Alejandra
    Sotelo, Julio
    [J]. SURGICAL NEUROLOGY, 2007, 67 (04): : 388 - 391
  • [9] Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma
    Chaichana, Kaisorn L.
    Pendleton, Courtney
    Chambless, Lola
    Camara-Quintana, Joaquin
    Nathan, Jay K.
    Hassam-Malani, Laila
    Li, Gordon
    Harsh, Griffith R.
    Thompson, Reid C.
    Lim, Michael
    Quinones-Hinojos, Alfredo
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (10) : 1422 - 1426
  • [10] Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis
    Chowdhary, Sajeel A.
    Ryken, Timothy
    Newton, Herbert B.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2015, 122 (02) : 367 - 382